Meeting
2016 ASCO Annual Meeting
Epidermal growth factor receptor mRNA expression in circulating tumor cells as a potential mechanism of molecular escape from regorafenib therapy.
Authors
Satoshi Matsusaka
Department of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan
Satoshi Matsusaka , Yan Ning , Dongyun Yang , Wu Zhang , Diana L. Hanna , Shu Cao , Mitsukuni Suenaga , Satoshi Okazaki , Martin D. Berger , Heinz-Josef Lenz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 34, 2016 (suppl; abstr 11517)
DOI
10.1200/JCO.2016.34.15_suppl.11517
Abstract #
11517
Poster Bd #
214
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
SRC-homology 2 domain-containing phosphatase 2 (SHP2) in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD).
First Author: Rafael Rosell
Poster
2023 ASCO Annual Meeting
Nipavect: Phase II study of niraparib and panitumumab in advanced RAS WT colorectal cancer.
First Author: Olatunji B. Alese
Poster
2017 Gastrointestinal Cancers Symposium
Nintedanib (N) plus best supportive care (BSC) versus placebo (P) plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Subanalysis of the phase III LUME-colon 1 study in pts by prior regorafenib (R) treatment.
First Author: Heinz-Josef Lenz
Poster
2014 ASCO Annual Meeting
Amphiregulin (AREG) SNP rs161511 to predict cetuximab efficacy independent of AREG mRNA levels: Data from FIRE3 (AIO KRK-0306).
First Author: Sebastian Stintzing